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1. Introduction 
Encephalitides, an acute infection of the brain parenchyma, are characterized by fever, 
headache and altered consciousness. Neurological deficits and focal or generalized epileptic 
seizures may also be seen. There are important differences in clinical presentations between 
encephalitides caused by viruses. While some viral encephalitides, such as Herpes simplex 
virus type-1 (HSV type-1) encephalitis, cause sporadic infection; others, such as Japanese B 
encephalitis virus and Eastern equine encephalitis virus, cause epidemic infections with 
specific geographic distribution. Some viruses like HSV cause fulminant encephalitis 
leading to death within a couple of days whereas viruses such as Measles virus can cause 
progressive subacute sclerosing panencephalitis lasting several months and years. HSV 
type-1, HSV type-2, LaCrosse encephalitis virus, St. Louis encephalitis virus usually causes 
encephalitis in healthy individuals, whereas HSV type-1, Cytomegalovirus, Varicella-zoster 
virus, Epstein-Barr virus, Human herpes virus type-6 and Enteroviruses are associated with 
encephalitides in immunodeficient or immunocompromised patients (Mathewson 
Commission, 1929; Meyer et al.,1960; Roos,1999).  
Herpes simplex virus (HSV) is the most common cause of sporadic fatal encephalitis 
(Mathewson Commission, 1929; Meyer et al.,1960; Smith et al., 1941). Smith et al. detected 
inclusion bodies consistent with HSV infection from a newborn’s brain with encephalitis 
and virus was isolated from brain tissue then (Smith et al., 1941). The first adult case of HSE 
was reported by Zarafonetis et al. (Zarafonetis et al., 1944). The pathological findings in this 
patient's brain were prominent perivascular cuffing of lymphocytes and a large number 
small hemorrhages in left temporal lobe. Later in several studies, this temporal lobe 
localization was reported to be characteristic for HSE in patients older than 3 months. In the 
mid 1960s, Nahmias and Dowdle found two distinct antigenic type of HSV, as HSV type-1 
and HSV type-2 (Nahmias & Dowdle, 1968).  
The HSE, observed in adults, is caused by HSV type-1 predominantly (Dennett et al., 1997; 
Whitley & Lakeman, 1995). HSV type-2 is rarely seen in healthy adults and usually causes 
benign CNS infection, whereas severe meningoencephalitis is seen in immunosuppressed 
individuals (Mommeja-Marin et al., 2003). Herpes neonatorum, transmitted from perinatal 
area, causes severe encephalitis in neonates (Corey et al., 1983). HSV type-1 and HSV type-2 
are from Herpesviridae family. The common feature of Herpesviridae family is that they 
stay in life-long latent (persistent) form in the organism and they can reactivate later leading 
recurrent infections. Also other viruses from Herpesviridae group may lead CNS diseases 
(Garcia-Blanco et al., 1991).  
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Herpes simplex encephalitis (HSE) continues to be one of the most devastating infections of 
the central nervous system despite available antiviral therapy. In patients taking no 
treatment or receiving an ineffective anti-viral treatment such as Idoxuridine and Cytosine 
Arabinoside, the mortality rate is higher than 70 % (Chien et al., 1975; Longson, 1979; 
Whitley et al, 1977; Whitley et al, 1981). Approximately one-third of all patients diagnosed 
with HSE are composed of children and adolescents. In clinical diagnosis, an 
encephalopathic disease process with focal neurological symptoms is seen. However, these 
clinical findings are not pathognomonic, and many other disorders involving the central 
nervous system have these symptoms and these diseases can mimic HSE. 
In neurodiagnostic evaluation, demonstration of temporal lobe edema and /or bleeding 
with magnetic resonance imaging (MRI) is supportive for diagnosis. In 
electroencephalogram, spike and slow wave activity is observed. HSV isolation from brain 
tissue with brain biopsy was a diagnostic method used in the past. Today, detection of 
herpes simplex virus (HSV) DNA by cerebrospinal fluid polymerase chain reaction (PCR) is 
the gold standard for diagnosis. PCR is an excellent test and preferred over brain biopsy. 
95% of cases can be diagnosed by PCR (Chien et al., 1975; Longson, 1979; Whitley et al, 1977; 
Whitley et al, 1981). However in the early period after the onset of the disease, false-negative 
results by PCR may be seen. 
Acyclovir is the preferred method of treatment and administered 10 mg / kg every 8 hours 
for 21 days. Even if the treatment is started early after the onset of the disease, significant 
neurological deficits are observed in nearly two-thirds of the surviving patients. Today in 
current studies, quantitative prognostic value of viral DNA by PCR both at the beginning as 
well as at the end of treatment and contribution of long-term anti-viral therapy for 
improvement in neurological outcomes are investigated (Tyler, 2004).  
2.1 Etiology  
HSV type-1, member of the herpes virus family, is an enveloped-virus with a large (150-250 
nm in size) linear double-stranded DNA (Mathewson Commission, 1929). The viral particle 
is wrapped from outermost by an envelope, which is made of lipid. Viral DNA is encased 
within a capsid that is 85-110 nm diameter in size. The structure between the envelope and 
capsid is called tegument (Davison & Clements, 2005; Jerome & Ashley, 2003; Whitley, 
1996). In these 3 layers, there are 25-30 structural proteins which form the structure of the 
virion. There are 11 glycoprotein protrusions on the surface of the envelope with antigenic 
properties (gB, gC,….., gM). While gB and gD glycoproteins play an important role in the 
attachment to and entrance of the virus into target cells, gC, gE, gG, gI, gJ and gM 
glycoproteins play an important role in the penetration of the virus to the cell. gG is the 
major protein providing antigenic specificity of the virus (Erturk, 1999; Whitley,1996; 
Whitley & Roizman, 2001). gC glycoprotein binds to C3b component of complement system 
on the surface of infected cells. gE and gI glycoproteins bind to Fc part of IgG. The 
antibodies against to these envelope glycoproteins neutralize the infectivity of the virus with 
competitive binding to receptors. The protein named as transinducing factor (Vmw65) is 
localized in the region of tegument and related with latent or lytic infection (Mathewson 
Commission, 1929). Capsid, surrounding the viral genome, and consists of 162 kapsomers 
and is icosahedral in shape. Icosahedral structure of capsid is supported by structural 
proteins VP21 and VP22a particularly (Davison & Clements, 2005; Jerome & Ashley, 2003; 
Whitley, 1996). Non-structural proteins, so-called Infected cell proteins (ICP), play role in 
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DNA replication and transcription regulation. In addition, there are some other non-
structural proteins that act especially as enzymes. The most important of these enzymes are; 
DNA polymerase, deoxyribonuclease, ribonucleotide reductase, protein kinase and 
thymidine kinase. These enzymes,in similar, have also important roles in important 
functions such as viral DNA replication (Erturk,1999; Whitley & Roizman, 2001). 
HSV is unstable in the external environment. HSV is heat-labile. Half-life of the virus is 1.5-3 
hours at 37 ° C. The virus is inactivated at temperatures above 56 ° C. It can live for months 
at -70 ° C and protect its infectivity. It can remain alive for 48 hours at 4 ° C in humid 
conditions, while it is inactivated under dry conditions. It is sensitive to most proteolytic 
enzymes, such as trypsin, protease and aminopeptidase. Like other enveloped viruses, it is 
easily inactivated by ether, phenol, chloroform and formalin (Mathewson Commission, 
1929; Whitley, 1996). 
2.2 Epidemiogy 
The most common cause of acute viral encephalitis is Varicella zoster virus and it causes a 
mild encephalitis course (Koskiniemi et al., 2001). Herpes simplex viruses are the agents in 
approximately 10% of all acute encephalitides. The most common cause of acute sporadic 
viral encephalitis (95% cases) is Herpes Simplex Type-1 and it causes fatal encephalitis. The 
incidence of HSE is reported as 2-4/1 million/year (Johnson, 1998; Koskiniemi et al., 2001; 
Levitz, 1998; Rantalaiho et al., 2001). All over the world, irrespective of the seasons, 
encephalitis occurs sporadically in all ages and does not show gender difference throughout 
the year (Whitley et al., 1982). Virus usually spreads via infected aerosols and through saliva 
(Griffin, 2000; Loon et al., 2004; Serter, 2002). Throat carriers are responsible from person to 
person spread of infection. The infection occurs with direct inoculation of the agent to oral, 
ocular, genital, anal mucosa, respiratory tract and bloodstream of susceptible people. No 
infection is seen through intact skin. Viral antibodies are positive in 70-90% of adults 
(Griffin, 2000; Roos,1999).  
HSV-induced central nervous system (CNS) infections are much more severe than all other 
viral infections observed in the human brain. Today, the incidence of HSE is estimated to be 
approximately 1/250.000-500.000. Studies in United States, Britain and European countries 
show similar incidence rates and annual incidence has been reported as 1/300.000 (Longson, 
1984; Skoldenberg et al., 1984). It was reported that medical costs for the young and adult 
patients hospitalized with the diagnosis of HSE in the United States in 1983 was more than $ 
1 billion (Khetsuriani et al., 2002; Straus et al., 1985). HSE does not show seasonal variation 
throughout the year and can be seen in individuals of all ages. Approximately one-third of 
the cases are younger than 20 years and half of the patients are over the age of 50 (Whitley et 
al., 1982a, Whitley et al., 1982b). 
2.3 Pathology and pathogenesis 
HSV replication is a regular and a multi-step process. All herpes viruses induce long-term 
latent infections in the host. However, this process is not fully elucidated (Griffin, 2000). 
Pathological changes are characterized by ballooning degeneration of cells infected with 
replicated HSV and accumulation of chromatin within the cell nucleus following cellular 
core degeneration. Cells lost intact plasma membranes. During this process; multinucleated 
giant cells are formed by amitotic dividing of the nucleus. Also inside them, Cowdry type A 
intranuclear inclusion bodies formed by newly synthesized DNA masses are observed 
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(Serter, 2002). Usually, a clear area surrounded by chromatin is seen around the zone 
characterized by an obvious eosinophilic homogeneous appearance. These intranuclear 
inclusion bodies are supportive for diagnosis and usually observed in the first week of the 
infection, whereas they are only seen in 50% of patients. Then, migration of mononuclear 
cells in infected tissues, showing host immune response, can be detected. In this acute stage 
of HSE, congestion and / or bleeding may also be seen in the inflammatory field formed by 
mononuclear cells particularly in temporal lobes. This is usually asymmetrical in adults 
whereas a more diffuse involvement is seen in newborns (Boos & Esiri, 1986). Similar 
involvement can be seen in the adjacent limbic areas. After about 2 weeks, neurophagia with 
necrosis is observed in neurons and glial nodules occur. In addition, host immune response 
is also responsible for the severity of tissue damage (Serter, 2002).  
Microscopic examination is usually abnormal due to enlargement of the involved areas. In 
the first stages, histological changes may not be dramatic and they are non-specific. 
Congestion of capillaries was observed in the cortex and all other changes, including 
petechiae, were significantly observed in subcortical white matter. Vascular changes are 
usually seen in the infection areas of hemorrhagic necrosis and perivascular cuffing. 
Perivascular cuffing becomes apparent in the second and third week of the infection. Glial 
nodules have been observed more frequently after the second week of the infection (Boos & 
Kim, 1984; Kapur et al., 1994). Microscopic appearance is characterized by inflammation 
dominated by necrosis, extensive perivascular mononuclear cell infiltration, gliosis and 
satellitosis neuronophagia (Boos & Esiri, 1986; Garcia et al., 1984). The most striking finding 
is observation of large areas of hemorrhagic necrosis reflecting the area of infection. In the 
later stages of the disease, oligodendrocytic participation and gliosis (astrocytosis as well) 
has been observed more often. 
2.4 Pathogenesis of human disease 
HSE development occurs by reaching of CNS disease causing virus to the brain. Course of 
illness and disease pathogenesis in humans is well known, but the arrival of virus to brain 
and issues related to reactivation of the virus present in the temporal lobe is still not clear. 
Partial understanding of the pathogenesis of HSE is a common feature for all age groups. 
Primary and recurrent HSV infections lead CNS disease eventually.  
Primary infection in humans occurs via secretion of HSV and its spread to a seronegative 
sensitive person. For the occurrence of infection, contact of virus with mucosal surfaces or 
damaged skin is required (Cook & Stevens, 1973). As a rule, primary infection of HSV type-1 
is often associated with oral mucosal disease in children or young adults. Tissue lesion, as a 
result of local virus replication, is usually in the form of asymptomatic gingivostomatitis 
(Schmutzhard, 2001). Then, viruses penetrate to mucosal receptors. As a result of viral 
replication in primary infection area, HSV Type-1, due to its affinity to sensitive and 
autonomic nerves, settles into the trigeminal nerve and olfactory tract ganglion neurons 
which are usually found in dorsal root ganglions.  
Studies on the reactivation of the virus within the CNS have shown that certain viruses have 
enhanced neurotropism potential. Classical studies on animals proved that HSV reaches 
CNS through by both olfactory and trigeminal nerves (Johnson et al., 1968). However, 
especially in primary infection of humans, usage of trigeminal nerve by virus as a means of 
access to the CNS in a more preferred way is still a controversial issue. In HSE, settlement of 
the virus in temporal lobe through this route and spreading into the limbic system with 
www.intechopen.com
 Herpes Simplex Type 1 Encephalitis 
 
107 
replication is called as anatomical spread hypothesis. In studies conducted on patients 
diagnosed with HSE, herpes virus particles along the olfactory tract were shown by electron 
microscopic examination of tissue samples in some patients (Dinn, 1980; Ojeda et al., 1983; 
Twomey et al., 1979; Whitley et al., 1986).  
Animal studies showed that virus transmission to CNS has occurred through a neurological 
pathway via olfactory tract and an infection is seen in animal brain regions similar to the 
medial temporal lobes in humans (Schlitt et al., 1986; Stroop & Schaefer, 1986). However, for 
humans, there is no evidence for such an access route. HSV reactivation is another confusing 
issue in the process of HSE formation. There are documentations regarding virus latency in 
infected brain tissue (Rock. & Frasher, 1983),  but there is not enough information about the 
virus reactivation also taking place in this area. The disease has been suggested to occur via 
neuronal transmission of reactivated growing viruses to CNS right after virus reactivation in 
peripheral regions such as olfactory bulb or trigeminal ganglia (Davis & Mclaren, 1983; 
Griffith et al., 1967; Johnson et al., 1968; Stroop & Schaefer, 1986). As a result, HSV type-1 
settles in its preferred remote residential areas of CNS such as the basal parts of the frontal 
lobes and limbic system parts of the temporal lobe via retrograde axoplasmic transport 
(Barnett et al., 1994; Cook & Stevens, 1973; Schmutzhard, 2000). Then type HSV-1 remains 
latent until another viral replication occurs. Also in animal studies, it was shown that virus 
can remain latent in the neuronal sub-populations of brain stem and cerebellum (Baringer & 
Pisani, 1994; Boggian et al., 2000; Lewandowski et al., 2002; Rock. & Frasher, 1983). 
In the later stages, reactivation occurs in nuclei of these latent virus infiltrated neurons and 
virus proliferation is seen. Viral DNA synthesis is built together with the virus capsule and 
an acute infection occurs clinically (Hill, 1985). This asymptomatic acute infection, caused by 
reactivation of HSV type-1, is characterized with infections such as herpetic 
keratoconjunctivitis in residual regions (oropharyngeal, orofacial and corneal) of 
distribution area of trigeminal ganglia. This infection is also accompanied by typical 
mucocutaneous vesicular eruptions (such as herpes labialis) and mucosal ulcers. In addition, 
proliferating viruses of viral reactivation in this acute infection period are secreted to the 
external environment and constitute a source of infection for HSV type-1 (Schmutzhard, 
2001).  
In this infection situation, formation of infectious virus particles is accompanied by 
deterioration in host cells. These events are shown in various animal studies (Hill, 1985). 
This infection situation in latent areas can be diagnosed at this stage by demonstration of 
viral DNA content (20-100 copies per cell) in neural cell nuclei. Detection of viral antigenic 
structure is rarely possible in the latent phase. In general, synthesis of the single viral gene, 
called Latency Associated Transcripts (LATs), occurs in infiltrated cells. In many studies, 
LATs are shown to be responsible from prevention of apoptosis in infiltrated cells and that 
they reflect late viral reactivation (Millhouse & Wigdahl, 2000; Perng & Ciacci-Zanella, 
2000). 
Eosinophilic inclusion bodies containing viral antigen and herpes virus particles are found 
in related neurons and glial cells. Chemotherapy and UV-rays trigger immune system 
changes, latent virus activation leading to formation of the HSE and development of herpes 
labialis. HSE has been noticed to be not more frequent in immunosuppressed people. In 
several studies, it was observed that the disease had a more severe course in immune-
competent patients. Because, the CNS disorders are estimated to occur as a result of serious 
contributions of immune-mediated mechanisms (Hudson et al., 1991; Levitz, 1998; Whitley 
& Lakeman, 1995). 
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Recurrent reactivation (such as herpes labialis infections) and viral replication rarely causes 
acute hemorrhagic necrotizing encephalitis (involving temporal cortex and the limbic 
system) (Barnes & Whitley, 1986; Roos,1999). Despite extensive researches in animal models, 
pathogenesis of HSE is not fully explained. 3 different hypotheses have been proposed in 
formation of the HSE via HSV type-1 (Levitz, 1998; Schmutzhard, 2001; Whitley & Lakeman, 
1995). According to examinations conducted by National Institute of Allergy and Infectious 
Diseases (NIAID) and Common Antiviral Study Group (CASG), the primary infection has 
been reported to occur in about one-third of patients with HSE. After primary HSV 
infections, direct CNS invasion from nasal mucosa of the mouth and throat occurs through 
trigeminal nerve and olfactory tract. Often patients with primary infection are younger than 
18 (Barnett et al., 1994; Davis & Johnson, 1979). Whereas in two-thirds of the cases, the 
disease occurs in the presence of existing antibodies (Nahmias et al., 1982). In 1/3 of HSE 
cases in this group, reactivation is seen as a result of recurrent herpes diseases in latent 
viruses in trigeminal ganglion and viruses multiply to cause a retrograde infection (Johnson, 
1998; Schmutzhard, 2000). Endonuclease analysis of peripheral (labial) and CNS DNA 
isolates were compared and often the isolates were identified as similar. Only 10% of the 
patients had a medical history of recurrent herpes labialis (Nahmias et al., 1982). Also in 1/3 
of the HSE cases, reactivation of existing latent viruses in CNS, such as brain stem and 
cerebellum, plays role (Levitz, 1998; Rock. & Frasher, 1983; Whitley & Lakeman, 1995). 
Finally, acute hemorrhagic necrotizing viral encephalitis in gray matter, particularly basal 
portions of the frontal lobe and limbic system of temporal lobe is seen (Barnett et al., 1994). 
Bilateral asymmetrical inflammation of temporal lobes is the main finding and intracerebral 
amygdaloid nucleus, hippocampus and insular region involvement is usually observed 
(Mutluer, 2002).  
2.5 Clinical variability 
Primary HSV infection and first viral replication usually occurs in the oropharyngeal 
mucosa. During this asymptomatic period, influenza infection findings, such as fatigue and 
general feeling of illness, are observed. Then a period of symptomatic disease which is 
characterized by high fever, headaches and difficulty in chewing caused by cheek and gum 
mucosa lesions begins and this period lasts 2-3 weeks. 
High fever (89%) and headache (78%) are the most common non-specific symptoms seen in 
the early period of HSE. Also within this period, the basic neurological disorders are added 
to the course. Listed among the characteristic findings; changes in level of consciousness 
(confusion, hallucinations and personality changes, etc.), from sleep tendency leading to 
coma, were observed in 96%. Personality change was observed in 61%, whereas dysphasia 
was observed in 51%. Sensory aphasia (Wernicke's aphasia) due to dominant hemisphere 
involvement in the early period describes mild organic psycho-syndrome seen in HSE. 
Epileptic seizures (focal and generalized) are observed in 38% of patients and to a lesser 
extent, 36%, hemiparesis accompanies. Papilledema was observed in 14%, whereas ataxia is 
rarely observed (Bewermeyer et al., 1987; Johnson, 1998; Maihofner et al., 2002; 
Schmutzhard, 2000; Whitley et al., 1982). It was reported that meningeal irritation findings 
were not significant. Symptoms usually reach maximal level in 2-3 weeks (Loon et al., 2004; 
Roos,1999). Nothing is observed in herpetic skin flora (Shoji et al., 2002). In late HSE period, 
findings ranging from neurological residual syndrome, mild grade cognitive deficits, 
behavioral changes or personality changes are seen. Mostly post-infectious therapy-
refractory epilepsy remains permanent (Bewermeyer et al., 1987; Schmutzhard, 2001).  
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However, completely atypical or chronic illness courses have also been reported  
(Bewermeyer et al., 1987; Panagariya et al., 2001; Whitley et al.,  1989). Besides very mild 
courses, recurrent brain stem encephalitides were also defined (Klapper at al., 1984; Tyler et 
al., 1995). Because of this diversity of clinical symptoms, the diagnosis of the disease remains 
difficult and this causes the virostatic therapy to be applied very late.  
Active mucocutaneous HSV infection accompanying immunocompromised patients is 
rarely observed with immunocompetent patients. Immune-suppression increases the risk of 
reactivation of latent HSV in cranial nerves and immune-suppressive agents in animal 
model studies have been shown to induce HSE. HSV type-1 was described as the main 
factor in brain stem and limbic system encephalitis in AIDS patients. Immune reaction that 
causes classical necrotizing encephalitis in advanced AIDS cases may not be seen 
(Roos,1999). As a result of some studies, the risk of reactivation of HSE during intracranial 
surgery was found and therefore pre-, peri-and post-operative application of Acyclovir 
treatment was proposed (Bourgeois et al., 1999). In an experimental study, induction of 
hypothalamic-pituitary adrenocortical axis and production of IL-1 and PG-E2 in the brain, 
independent of viral replication, by HSV type-1 was shown and also HSV type-1 was 
suggested to be a factor in the emergence of the symptoms, such as high- fever, motor 
hyperactivity and aggressive behavior. 
2.6 Diagnosis 
Clinical findings in HSE are non-specific so they cannot be used for empirical diagnosis. The 
presence of clinical symptoms and a localized lesion in the temporal lobe usually reflects 
HSE, but other diseases can also mimic this condition (Whitley et al., 1989). CSF examination 
is indicated for patients with mental changes even if intracranial pressure is increased. In 
addition, presence of a lesion in brain computed tomography (CT) or magnetic resonance 
imaging (MRI) was found to be related with poor neurological outcomes (Domingues et al., 
1997; Domingues et al., 1998a; Domingues et al., 1998b).  
In HSE cases in which viral replication cannot be blocked with early treatment, surviving 
patients are known to suffer heavy and large number of neurological sequelae. Therefore, 
early diagnosis is of great importance. Diagnosis is made with clinical symptoms, MRI, EEG 
and CSF examination. The sensitivity is increased with the combination of these 
neurodiagnostic tests, but the specificity is still insufficient (Griffin, 2000; Dupuis, 1999). In 
the past, the only method used to prove HSE was brain biopsy, whereas today HSV-DNA 
presence in CSF with PCR method is valid for the diagnosis (Lakeman & Whitley, 1995).  
Specificity and sensitivity of brain CT for diagnostic aspect is less. Hemorrhagic brain 
lesions in temporal lobe on CT show areas of low density causing localized mass effect 
(Enzmann et al., 1978; Zimmerman et al., 1980). Especially bilateral involvement of temporal 
areas at the later stages of the disease shows that the disease is resistant to therapy. Typical 
changes in HSE, correlated with brain CT, show large brain damage but these changes are 
not compatible with the prognosis (Morawetz et al., 1983).  
When HSE is suspected; cranial MRI should be applied as an emergency to prove 
neuropathologic changes very early. MRI suggests the findings of HSE earlier than CT 
(Schlesinger et al., 1995). Because MRI is a more sensitive and specific diagnostic tool, it is 
used instead of CT scans in majority of patients (Schlesinger et al., 1995; Sener, 2001, 2002). 
The characteristic MRI finding of HSE is hyperintense areas in inferior lobes including the 
medial part and insula and this characteristic involvement may also be observed in the 
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frontal and parietal lobes, furthermore bilateral temporal lobe involvement has been 
reported to be pathognomonic as well  (Aribas, 1996; Gordon, 1999; Roos,1999). This 
frontobasal and temporobasal hyperintense signal changes and diffusion limitation 
especially observed in T2-FLAIR sequences are typical (Djukic et al., 2003; Maihofner et al.,  
 
 
Fig. 1. T1-SE images in axial and sagittal planes, T2-TSE images in axial and coronal planes, 
FLAIR images in axial plane, T1-weighted SE images in axial, coronal and sagittal planes 
after intravenous contrast agent administration were obtained. Diffusion-weighted images 
of brain were obtained (b=0 b= 500, b=1000sn/mm2 and ADC mapping). Lesion consistent 
with herpes encephalitis was observed in examination of right supratentorial region. The 
lesion was in the temporal lobe, involving parahippocampal gyrus and the hippocampus, 
and was extending to frontobasal region. The lesion was hyperintense on T2 and FLAIR-
weighted sequences, showing diffusion limitation and no contrast enhancement after 
intravenous injection of Gadolunium.  
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Fig. 2. Brain MR Spectroscopy evaluation of another patient was performed with CSI 
technique and TE of 30ms, 135ms and 270ms. Millimetric nodular lesions consistent with 
encephalitis were seen in right frontotemporal region, brain stem diffusely involving pons 
and left centrum semiovale. In spectroscopic examination, no significant choline peak was 
detected and a decrease was observed in NAA/Creatinine ratio. 
2002; Schroth et al., 1987). In other sequences, parenchymal injury observed in the initial 
stage has been documented as areas of abnormal diffusion and these areas was observed to 
be reversible with virostatic treatment (McCabe et al., 2003). In addition, as a result of 
further studies, the severity of involvement observed in cranial MRI was reported to be 
compatible with the severity of clinical symptoms (Lamade et al., 1999).  
CSF examination is another helpful method in the diagnosis of HSE and guiding in 
differentiation of diseases that mimic HSE. CSF examination is particularly indicated for 
patients with mental changes. CSF is transparent and cerebrospinal fluid pressure is usually 
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increased in HSE (Whitley et al.,  1989). Polymorphonuclear leukocyte domination is seen in 
CSF in the early periods of HSE (Griffin, 2000). With disease progression, increase in WBC 
(lymphocytic pleocytosis) and protein level is determined. The average protein and WBC 
counts in CSF are approximately 100 mg / dL and 100 cells / L, respectively. The frequency 
of lymphocytic pleocytosis in CSF, especially when compared to patients with diseases that 
mimic HSE, is determined to be higher (Whitley et al.,  1989). HSE leads to early 
hemorrhagic encephalitis so erythrocytes are often seen in CSF and this is a helpful finding 
for diagnosis (Mutluer, 2002). CSF glucose level is almost always within the normal range 
but reduction of glucose level due to consumption is typical in bacterial meningitis (Griffin, 
2000; Roos,1999). In 5-10% of cases observed especially in children, the first evaluation of 
CSF examination can be found normal. However, CSF examination should be repeated 
within 24 hours, so in most cases, abnormalities can be observed (Whitley et al.,  1989).  
The success of CSF virus culture does not exceed 5% in encephalitis, so detection of nucleic 
acid by PCR in CSF at the first two weeks of infection and intrathecal antibodies at late 
period (after the 10th day) is recommended (Linde et al., 1997). Intrathecal specific IgG 
positivity begins at 10-12th day reaches its peak level at 20th day and may continue for years. 
Timing of CSF sampling is important for PCR. CSF sampling in early stage (first 48-72 
hours) or after treatment can lead to negative results in PCR. In cases that the test is negative 
but there is clinical suspicion, repeated sampling of CSF for PCR and investigation of 
intrathecal antibodies at late stage may be diagnostic (Cinque et al., 1996; Puchhammer-
Stöckl et al., 2001; Sauerbrei & Wutzler, 2002). 
2.6.1 PCR detection of viral DNA 
The most commonly used method for the isolation of virus is cell culture cultivation. 
However, CSF viral cultures of HSV type-1 are often negative (Griffin, 2000; Serter, 2002). 
Therefore, viral nucleic acid exploration by PCR in the CSF has become very important in 
patients with encephalitis. With this method, there is a possibility of detecting even small 
amounts of DNA and the test results within 24 hours often. Over time, CSF HSV DNA 
detection by PCR has become the gold standard for diagnosis (Boos & Esiri, 1986; Davis & 
Mclaren, 1983; Dinn, 1980; Hill, 1985; Radermecker, 1956). Different genome regions 
(thymidine kinase, DNA polymerase, GPB, GPC, GPG, GPD, etc.) can be used for PCR 
(Cinque et al., 1996; Tang et al., 1999). Studies conducted by NIAID and CASG reported that 
this method had a very high sensitivity (98%) and specificity (94%). In 80% of tested 
samples, HSV-DNA positivity still remained within 1 week or more despite anti-viral 
treatment in HSE patients. As a result of the studies, HSV-DNA positivity in CSF by PCR 
was 100% within 10 days after the onset of symptoms, 30% in 11-20th and 19% in 21-40th  
days (Griffin, 2000; Roos,1999; Serter, 2002). The recently developed real-time PCR method 
has also examined CSF samples from patients with suspected HSE. As a result of the 
studies, a statistical correlation between the amount of virus (viral DNA copies / mL) and 
decrease in level of consciousness was showed, and a direct correlation was reported 
between CSF viral load (HSV-DNA amount), clinical outcome and prognosis  (Domingues 
et al., 1998a; Domingues et al., 1998b;  Domingues et al., 1997). PCR negativity shows either 
the absence of virus in the sample or presence of inhibitory activity. False-negative results 
may be observed in the PCR at the beginning of HSE symptoms (the first 24-48 hours) or 10 
days to 2 weeks after onset of symptoms. False-negative results may also be observed in 
hemorrhagic CSF samples due to inhibition of the PCR reaction by erythrocytes (Serter, 
2002).  
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The presence of HSV-DNA in CSF shows CNS infection due to HSV. However, in 
immunocompromised individuals, especially low amounts of HSV-DNA may not always be 
the evidence of the disease. Viral DNA quantitation may be guiding in diagnosis (Aberle & 
Puchhammer-Stöckl, 2002). Although the clinical significance of quantification of the 
controversial yet, as real-time PCR quantitation can be made with precision and speed, it 
can provide the knowledge needed in this regard. HSV-DNA in CSF can remain positive up 
to 1 week after beginning of acyclovir treatment (Cinque et al., 1996). HSV-DNA positivity 
in spite of treatment was associated with poor prognosis (Najioullah et al., 2000).  
Though difficult to perform, brain biopsy protects its value in confirmatory of diagnosis 
(Djukic et al., 2003; Maihofner et al., 2002; Schroth et al., 1987). Isolation of HSV from the 
tissue samples taken by brain biopsy is sensitive (96%) and specific (100%) method for 
diagnosis. However, HSV-DNA detection in CSF by PCR has replaced brain biopsy due to 
being a less invasive method, easy to implement and achieving faster results. Brain biopsy is 
preferred in cases where CSF findings are atypical, HSV-DNA detection in CSF by PCR 
cannot be done, antibody tests are negative and MRI and EEG findings are non-specific 
(Roos,1999). In patients with suspected HSE, HSE rate confirmed by brain biopsy has been 
reported to be 45% (Whitley, 2004). Brain biopsy procedure-related acute and chronic 
complications are observed in approximately 3% of patients. Brain sample collection from a 
diseased area with incision has the potential for acute disease and can cause epileptic 
seizures at chronic stage. As a result, even though in some cases it is confusing, brain biopsy 
is a helpful method in diagnosis. 
2.6.2 Serologic evolution 
Demonstration of HSV antigens via immunoperoxidase method is specific in diagnosis. 
Viral particles can be shown by electron microscopy in 50% of all cases (Serter, 2002). 
Detection of anti-HSV antibodies in CSF is another method used for the diagnosis of HSV 
encephalitis (Cesario et al, 1969). Detection of specific antibodies in CSF may be diagnostic 
when other methods are inadequate and at periods of removal of virus from CSF (usually 
the first 1-2 weeks after infection) (Lanciotti et al., 2000). Detection of specific IgM in CSF is 
diagnostic (Holzmann, 2003; Petersen & Marfin, 2002). Detection of specific IgG in CSF is 
also significant. However, transition of IgG from serum to CSF may be seen as a result of 
blood-brain barrier disruption, so demonstration of intrathecal synthesis is required. For this 
purpose, specific antibodies are examined quantitatively in serum and CSF samples which 
are taken at the same time and index obtained by proportion to each other is evaluated. If 
IgG in CSF is from serum origin, CSF / serum antibody ratio is 1/200-1/300 (Link & Muller, 
1971). During infection of the CNS, this ratio is increases in parallel with the increase in 
intrathecal antibody production. This method can be used as a reliable method except 
conditions causing polyspecific immune activation like Multiple Sclerosis or causing severe 
immunosuppression. Monteyne et al. compared a variety of index calculation formulas in 
detection of intrathecal HSV antibody response and determined that the results are 
compatible except with MS patients (Blennow et al., 1994; Linde et al., 1997; Reiber & Lange, 
1991). 
HSV type-specific IgM and IgG antibodies can be measured via immunological methods 
(neutralization, complement incorporation reaction, haemagglutination, indirect 
immunofluorescence, "radioimmunoassay" and ELISA) (Serter, 2002; Griffin, 2000). As a 
rule, detection of anti-HSV antibodies in CSF at the initial phase of the disease is not 
possible, but after 10-14 days, intrathecal production of virus-specific antibodies becomes 
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provable and thus makes a retrospective diagnosis possible. Especially between 2-4th weeks 
of infection, an increase in antibody titers is observed. A slight increase can be seen in 
subsequent recurrent infections, but specific antibody levels will persist for life (Pfister & 
Eichenlaub, 2001). However, the sensitivity and specificity of this method is low. Because 
increase in antibody titers up to four times at acute and convalescent stages of primary 
infection has been found neither sensitive nor sufficiently useful for the diagnosis of disease 
in patients diagnosed with HSE via other diagnostic procedures such as biopsy. In addition, 
increase in antibody levels may be detected in cases of herpetic infection causing fever, such 
as herpes labialis (Pfister & Eichenlaub, 2001).  
Increase in CSF anti-HSV antibody titers up to four-fold or greater is diagnostic. A 
significant increase (from 29% to 85%) is detected in 1 month till the onset. Four-fold  
 
 
Fig. 3. PLED formation was observed in left hemisphere of the brain in EEG of the patient.  
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increase in CSF anti-HSV antibody titers 10 days after the start of clinical symptoms are 
observed in only 50% of patients diagnosed as HSE with brain biopsy. Therefore, this test is 
valuable only in retrospective diagnosis. In addition, a CSF / serum antibody ratio value of 
20 or less has shown that there is no sensitivity during the first 10 days of the disease (Pfister 
& Eichenlaub, 2001).  
Increased pathological levels of markers (neuron-specific enolase, NSE and S-100, etc.) 
showing destruction of neuronal and glial tissue in the CSF may occur in HSE. In some 
studies, a correlation between brain injury and these values was able to be used to estimate 
prognosis. However, these parameters increase in cerebral ischemia and dementia so they 
are not HSE specific (Studahl et al., 2000). Similarly, observation of various signal peptides, 
proteins, cytokines and soluble cytokine receptors (Neopterin, beta-2 microglobulin, 
Interleukin, interferon gamma, etc.) should be understood as an expression of strong 
intrathecal immune response (Griffin, 2000; Serter, 2002). In addition, a few values also 
increased actively in the course of HSE correlated with increases (Aurelius et al., 1993; 
Aurelius et al., 1994; Griffin, 2000). Serial changes observed in intrathecal cytokine and 
chemokine levels in patients with HSE were investigated in 4 separate clinical trials in 
detail. As a result of these studies; HSE identified in the acute stages of IFN-ү and IL-6 levels 
increased and these values, confirming the diagnosis has been reported to be helpful  
(Asaoka et al., 2004; Aurelius et al., 1994; Ichiyama et al., 2008; Rösler et al., 1998).  
Another preferred method of early diagnosis of HSE is EEG. Frontotemporobasal 
dysrhythmia and a slowdown in frequency are observed in the EEG (Bewermeyer et al., 
1987; Whitley et al., 1982). Periodic lateralized epileptiform discharges (PLEDs) are relative 
characteristic findings resulting from the temporal lobe, observed as slow and sharp wave 
complexes repeatedly (Chien et al., 1977; Longson, 1984; Miller & Coey, 1959; Panagariya et 
al., 2001; Smith et al., 1975; Upton & Grumpert, 1970). They are often observed between 2-
15th days of the disease (Roos,1999). Early in the disease, abnormal electrical activity usually 
involves one temporal lobe, but as the disease progresses (over a period of 7-10 days), 
similar electrical activity may be observed in the contralateral temporal lobe. For the 
diagnosis of HSE, EEG sensitivity is 84% whereas specificity is only 32.5% (Enzmann et al., 
1978; Zimmerman et al., 1980).  
2.7 Differantial diagnosis 
In a study by NIAID and CASG; brain biopsy has been performed in 432 patients with 
encephalopathic foci and HSE was diagnosed in 45% of these patients. Diseases mimicking 
HSE were found in the remaining 55% of the cases (Whitley et al.,  1989; Whitley & Gnann, 
2002). In this group, brain abscess, tuberculosis, cryptococcal infection and brain tumor were 
detected in 38 patients and other viral encephalitides caused by enterovirus and Epstein-
Barr virus were detected in 38 patients. As a result, CNS HSV infection must be 
distinguished from these diseases mimicking HSV encephalitis (Roos,1999). Emergency 
medical treatment of patients with these statements is required even if PCR investigation of 
HSV-DNA is negative. 
2.8 Treatment and prognosis 
Idoxuridine is the first antiviral drug used for the treatment of HSE. However, as a result of 
a controlled clinical trial, this anti-viral agent was found to be ineffective and toxic (Chien et 
al., 1975). Later Vidarabine was defined as an effective therapeutic agent in the treatment of 
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HSE, but over time was replaced by Acyclovir, a more effective anti-viral agent (Whitley et 
al, 1977; Whitley et al, 1981).  
An improvement has been achieved in the prognosis of HSE with anti-viral therapy with 
acyclovir. In 1984 and 1986, two studies compared the efficacy and clinical use of Acyclovir 
and Vidarabine (Skoldenberg et al., 1984; Whitley et al., 1986). Acyclovir (9 - [2-
Hydroxymethyl] guanine) is a nucleoside analogue of deoxyguanosine. For the effectiveness 
of acyclovir in infected cells, phosphorylation with viral thymidine kinase is required. 
Acyclovir is converted to acyclovir monophosphate by viral thymidine kinase 
phosphorylation. The monophosphate is further converted into diphosphate and 
triphosphate by cellular kinases. Acyclovir-triphosphate inhibits viral DNA-polymerase 
selectively and competitively. In conclusion, the viral DNA chain is broken, and thus 
complete viral DNA synthesis is stopped. Due to lesser affinity to host cell DNA 
polymerases, causing a very little toxic effect in host cell is another important feature of 
Acyclovir-triphosphate (Dorsky & Crumpacker, 1987; Van Landingham et al., 1988).  
Acyclovir prevents virus proliferation but has no protective effect on primary and 
secondary immune-mediated damage that developed in previously virus infected cells. 
Therefore, early treatment is mandatory in patients with HSE and prophylactic Acyclovir 
treatment should be given even if HSE is suspected (Djukic et al., 2003; Dorsky & 
Crumpacker, 1987; Whitley et al., 1986). When administered intravenously, Acyclovir may 
crystallize and cause temporary renal failure. Therefore, intravenous drug should be 
administered both slowly and with adequate fluid support. Similarly, especially in patients 
with renal failure, renal function tests should be followed closely. Acyclovir should be 
applied intravenously every 8 hours at 10 mg / kg dose slowly (over 1 hour). The duration 
of treatment should be at least 14 days, but 21 days will be better (Djukic et al., 2003; Levitz, 
1998). Because worsening of the disease was defined in short-term treatment with 
reactivation of the virus (Baringer & Pisani, 1994; Van Landingham et al., 1988). CSF 
acyclovir levels are approximately 30-50% of corresponding plasma levels (Serter, 2002). 
HSV-DNA viral load in CSF may be used as a marker for treatment efficacy, but is 
independent from clinical course and cannot be correlated with it (Wildemann et al., 1997).     
Factors influencing the success and long-term clinical results in a positive way are patient 
age <30, Glasgow coma score (GCS) >10, <4 days of disease before the treatment with 
Acyclovir and early start time of the therapy (Griffin, 2000). Therefore, for the effectiveness 
of Acyclovir, the treatment should be initiated before a significant deterioration (GCS> 10) at 
the level of consciousness, the symptoms of initial phase (first 4 days) and particularly 
before start of the dominant temporal lobe hemorrhagic necrosis. Glasgow coma scale is the 
preferred scale indicating the level of consciousness in literature. Regardless of the age, a 
patient with a GC score 6 or less was shown to have worse treatment outcomes. Children 
and adolescents constitute 90% of HSE diagnosed patients under the age of 30. This group of 
patients likely to return to normal functions with mortality rates reported to be higher than 
in elderly patients (Whitley et al., 1986).  
The treatment of HSE is difficult and the mortality and morbidity rates still remain high 
despite treatment The mortality rate decreases from 70% to 20-30% with the use of acyclovir 
(Gnann & Salvaggio, 2004; Loon et al., 2004). In a study conducted by CASG and NIAID, 6 
and 18 months of treatment with Acyclovir decreased mortality rates to 19% and 28% 
respectively. Regardless of their age, 38% of patients return to normal lives with normal or 
minor neurological sequelae. However, even with treatment, most patients have a 
significant permanent neurological deficit. 9% of patients with neurological deficits had 
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moderate neurological sequelae, while 53% developed severe neurological sequelae that 
become permanent or fatal. Permanent neurological deficit or death occurs not by 
reactivation of HSV infection but as a result of the disease. The mortality rate is lower than 
that of children and adolescents, but studies did not show statistically significantly lower 
rates of mortality in elderly individuals. 
In a study recurrence of HSE was reported as 26%, while other studies have reported rate as 
4% and 8% (Ito et al., 2000). In a study by NIAID, no recurrences were observed after 
completion of treatment. As a result, even after Acyclovir treatment only a few patients had 
recurrence of HSE (Van Landingham et al., 1988; Wang et al., 1994). Treatment failure was 
attributed to post-infectious encephalomyelitis, reactivation of latent virus, inadequacy of 
14-day standard treatment regimen and possible drug resistance (Griffin, 2000). In addition, 
despite anti-viral treatment and clinical improvement, MRI follow-ups should be done 
frequently for progressive changes secondary to tissue damage (Lamade et al., 1999).          
As a result of a mutation in viral genes encoding thymidine kinase, resistance to acyclovir 
may occur in HSV. Resistant isolates of HSV had been identified in encephalitides of 
patients with organ transplant and HIV infection. Especially in HIV-infected patients, the 
prognosis is very poor if Acyclovir-resistant HSV infections were not treated (Roos,1999).  
Vidarabine may be used at a dose of 15 mg / kg / day in case of acyclovir resistance. 
However, although in vitro effect has been shown, Vidarabine was determined to be 
inadequate for treatment due to failure to reach target tissues and cells adequately and its 
side effects. In NIAID CASG studies, new morbidity development was demonstrated in 
about 15-20% of patients undergoing Vidarabine treatment during long-term follow-ups. In 
the same study, only 13% of patients treated with Vidarabine had none or mild neurological 
sequelae. 22% of the patients had moderate or severe neurological sequelae and death 
occurred in 55% of patients during the follow-up.  
Therefore, in case of intolerance to acyclovir, Foscarnet, a more effective anti-viral drug with 
lesser side-effects than Vidarabine, is suggested to be used (Schmutzhard, 2001). The effect 
of Foscarnet in the treatment of resistant HSV infections has been proven. 40 mg / kg 
Foscarnet administration every 8 hours for a period of 10-42 days is recommended in 
resistant cases. However, the recurrence rate is high after treatment with this anti-viral agent 
(Roos,1999; Serter, 2002). 
Famcyclovir, another alternative anti-viral drug used to treat HSE, is a pro-drug. In the 
organism, its structure changes into Pencyclovir, having a similar effect as acyclovir. 
However, its affinity for the viral-DNA polymerase is less than acyclovir. Therefore, the 
effectiveness for the treatment of HSE is less than acyclovir (Perry & Wagstaff, 1995). 
Valacyclovir, developed upon mild grade modification of acyclovir, reaches a high effect 
level when taken orally. However, a successful HSE therapy with Valacyclovir has been 
defined as casuistic in the literature. Similarly, as an alternative to acyclovir in the treatment 
of HSE; nucleoside analogues were used (Alrabiah & Sacks, 1996; Chan et al., 2000). 
Because the majority of cellular damage is immune-mediated, simultaneous use of 
corticosteroids in HSE treatment is controversial. However, in recent studies, combined 
therapies of Acyclovir and corticosteroids are mentioned (Meyding-Lamade et al., 2003; 
Thompson et al., 2000). 
Acute treatment of HSE should be done in intensive care unit. Intracranial pressure 
monitoring is required in order to intervene complications more quickly and in case of 
increased intracerebral pressure; mild hyperventilation and administration of osmotic 
diuretics (Mannitol, Gycerosteril) are recommended. If sufficient effect cannot be obtained 
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despite these treatments, craniectomy should be considered as an option to relieve 
intracranial pressure. Especially in cases complicated by tentorial herniation or massive 
brain edema, anterior temporal lobe resection and / or decompressive craniectomy is 
suggested to be useful (Griffin, 2000).  
Epileptic seizures in the acute phase should be treated with benzodiazepines, Valproic acid 
or diphenylhydantoin. In the treatment of permanent symptomatic epilepsy; similarly 
Carbamazepine, Oxcarbazepine and Valproic acid treatment is recommended. In addition, 
combinations of other anti-epileptic drugs like Lamotrigine, Topiramate or Levetiracetam 
are often necessary (Bewermeyer et al., 1987; Djukic et al., 2003; Pfister & Eichenlaub, 2001; 
Schmutzhard, 2001).  
3. Conclusion 
Marked improvement in prognosis has been achieved with modern diagnosis and Acyclovir 
treatment in the last 10-15 years. However, HSE is a severe, dangerous and progressive 
disease. As a result of an actual multi-center study, severe permanent neurological deficits 
or mortalities were reported in 35% of HSE patients despite treatment with Acyclovir 
(Raschilas et al., 2002). As documented in past studies, late admission to hospital and 
administration of anti-viral therapy are the reasons for the poor prognosis (Marton et al., 
1996; Raschilas et al., 2002; Schmutzhard, 2000). The prognosis is worse in older patients and 
those with impaired general and mental status before the onset of the therapy. Therefore, 
early diagnosis and anti-viral treatment should be done as quickly as possible with 
Acyclovir. 
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